Human Activated Lymphocyte Treated with Anti-CD3, CD16, CD56 Monoclonal Antibody and IL-2 |
Hong, Seon-Min
(Biocell Co. Immune Research Institute)
Lee, Dong-Wook (Biocell Co. Immune Research Institute) Kang, Jin-Gu (Department of Medicine, Yonsei University College of Medicine) Kim, Han-Soo (Department of Medicine, Yonsei University College of Medicine) Cho, Sung-Hoon (Biocell Co. Immune Research Institute) |
1 | Podack ER: Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol 7;11-16, 1995 DOI PUBMED ScienceOn |
2 | Liu CC, Walsh Cm, Young JD: Perforin: structure and function. Immunol Today 16;194-201, 1995 DOI ScienceOn |
3 | Henkart PA, Williams MS, Zacharchuk CM, Sarin A: Do CTL kill target cells by inducing apoptosis? Semin Immunol 9;135-144, 1997 |
4 | Rosenberg SA: Lymphokine-activated killer cells. A new approach to the immunotherapy of cancer. J Natl Cancer Inst 75;595-601, 1985 PUBMED |
5 | Azzoni L, Kamoun M, Salcedo TW, Kanakaraj P, Perussia B: Stimulation of Fc gamma RTIIIA results in phospholipase C-gamma 1 tyrosine phosphorylation and p56lck activation. J Exp Med 176;1745-1750, 1992 DOI ScienceOn |
6 | Berke G: The CTL kiss of death. Cell 81;9-12, 1995 DOI PUBMED ScienceOn |
7 | Oda H, Oda H, Hayashi M, Cho SH: Adoptive lymphocyte immunotherapy in Non-Hodgkin's lymphoma (NHL). Biotherapy 18;333-338, 2004 |
8 | Morgan DA, Rusetti FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrow. Sciences 193;1007-1009, 1976 DOI |
9 | Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18;175-182, 1997 DOI PUBMED ScienceOn |
10 | Klein C, Philippe N, Le Deist F, Fraitag S, Prost C, Durandy A, Fischer A, Griscelli C: Partial albinism with immunodeficiency (Griscelli syndrome). J Pediatr 125;886-895, 1994 DOI PUBMED |
11 | Boon T, Couline PG, van den Eynde B: Tumor antigen recognized by T cells. Immunol Today 18;267-268, 1997 PUBMED |
12 | Stinchcombe JC, Grffiths GM: Regulated secretion from hemopoietic cells. J Cell BioI 147;1-6, 1999 |
13 | Rosenberg S, Lotze M, Muul L: A progress report on the treatment of 157 patients with advanced cancer using lvrnphokine-activated killer cells and interleukon-2 or high dose interleukin-2 alone. N Engl J Med 316;889-897, 1987 DOI PUBMED ScienceOn |
14 | Taga K, Yamaguchi A, Bloom ET, Tosato G: Target-induced death by apoptosis in human lymphokine-activated natural killer cells. Blood 87;2411-2418, 1996 PUBMED |
15 | Berke G: The Fas-based mechanism of lymphocytotoxicity. Hum Immunol 54;1-7, 1997 DOI PUBMED ScienceOn |
16 | Herberman RB: Cancer Immunotherapy with Natural Killer Cells. Seminars in Oncology 3;27-30, 2002 |